Title |
Vemurafenib-resistant BRAF selects alternative branch points different from its wild-type BRAF in intron 8 for RNA splicing
|
---|---|
Published in |
Cell & Bioscience, December 2015
|
DOI | 10.1186/s13578-015-0061-7 |
Pubmed ID | |
Authors |
Masahiko Ajiro, Zhi-Ming Zheng |
Abstract |
One mechanism of resistance of the melanoma-associated BRAF kinase to its small molecule inhibitor vemurafenib is by point mutations in its intron 8 resulting in exons 4-8 skipping. In this report, we carried out in vitro BRAF RNA splicing assays and lariat RT-PCR to map the intron 8 branch points in wild-type and BRAF mutants. We identify multiple branch points (BP) in intron 8 of both wild-type (wt) and vemurafenib-resistant BRAF RNA. In wt BRAF, BPs are located at -29A, -28A and -26A, whereas in a vemurafenib-resistant BRAF splicing mutant, BPs map to -22A, -18A and -15A, proximal to the intron 8 3' splice site. This finding of a distal-to-proximal shift of the branch point sequence in BRAF splicing in response to point-mutations in intron 8 provides insight into the regulation of BRAF alternative splicing upon vemurafenib resistance. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Australia | 1 | 50% |
Unknown | 1 | 50% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 1 | 50% |
Science communicators (journalists, bloggers, editors) | 1 | 50% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 16 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Bachelor | 3 | 19% |
Researcher | 3 | 19% |
Student > Ph. D. Student | 3 | 19% |
Student > Doctoral Student | 2 | 13% |
Professor | 1 | 6% |
Other | 2 | 13% |
Unknown | 2 | 13% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 4 | 25% |
Agricultural and Biological Sciences | 4 | 25% |
Social Sciences | 2 | 13% |
Medicine and Dentistry | 2 | 13% |
Chemistry | 2 | 13% |
Other | 0 | 0% |
Unknown | 2 | 13% |